Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 65% of modeled bridge. Strengths: Occupancy Rate. Risks: Bed Count. Risk-adjusted uplift: $43.7M (vs $67.1M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $25.5M | $25.5M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $24.6M | $702K | $25.3M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $3.9M | $11.6M | $15.5M | $49.0M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $817K | $817K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 22.1% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $6.4M | $12.8M | $19.1M | $25.5M | $25.5M | $25.5M | $25.5M |
| Denial Rate Reduction | $0 | $6.3M | $12.6M | $19.0M | $25.3M | $25.3M | $25.3M | $25.3M |
| A/R Days Reduction | $0 | $5.2M | $10.4M | $15.5M | $15.5M | $15.5M | $15.5M | $15.5M |
| Clean Claim Rate | $0 | $408K | $817K | $817K | $817K | $817K | $817K | $817K |
| Cumulative | $0 | $18.3M | $36.6M | $54.4M | $67.1M | $67.1M | $67.1M | $67.1M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $67.1M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 49% / 7.4x | 54% / 8.6x | 58% / 9.8x | 60% / 10.4x | 62% / 11.0x |
| 9.0x | 44% / 6.2x | 49% / 7.3x | 53% / 8.4x | 55% / 8.9x | 57% / 9.4x |
| 10.0x | 40% / 5.3x | 44% / 6.2x | 48% / 7.2x | 50% / 7.7x | 52% / 8.2x |
| 11.0x | 35% / 4.5x | 40% / 5.4x | 44% / 6.2x | 46% / 6.7x | 48% / 7.1x |
| 12.0x | 31% / 3.9x | 36% / 4.7x | 40% / 5.5x | 42% / 5.9x | 44% / 6.2x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 0% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 6.5x, adding 2.0 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $222.1M | — | $222.1M | 17.4% |
| Year 1 | $228.8M | +$44.8M | $273.6M | 21.4% |
| Year 2 | $235.7M | +$67.1M | $302.8M | 23.7% |
| Year 3 | $242.7M | +$67.1M | $309.9M | 24.3% |
| Year 4 | $250.0M | +$67.1M | $317.2M | 24.8% |
| Year 5 | $257.5M | +$67.1M | $324.7M | 25.4% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $12.8M | $19.1M | $25.5M | $30.6M |
| Denial Rate Reductio | $12.6M | $19.0M | $25.3M | $30.3M |
| A/R Days Reduction | $7.8M | $11.6M | $15.5M | $18.6M |
| Clean Claim Rate | $408K | $613K | $817K | $980K |
| Total | $33.6M | $50.4M | $67.1M | $80.6M |
Peer Context — Where This Hospital Sits
Key metrics vs 37 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 17.4% | -5.3% | 5.7% | 12.5% | P78 |
| Net-to-Gross | 21.4% | 14.4% | 19.0% | 22.1% | P67 |
| Occupancy | 65.6% | 60.2% | 67.4% | 75.0% | P38 |
| Rev/Bed | $1.7M | $1.1M | $1.3M | $1.8M | P67 |
| Exp/Bed | $1.4M | $1.0M | $1.2M | $1.6M | P65 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.